Company news
Orthocell Ltd (ASX:OCC) news
Every Orthocell Ltd press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Q4 FY26 ASX Investor Presentation
July 13, 2026
Orthocell Appoints Thailand Distributor for Remplir
July 2, 2026
Remplir™: Australian Nerve Repair Device Supports Victims of War in Ukraine
June 28, 2026
First Sales of Remplir Achieved in US$75m Canadian Market
April 29, 2026
Compelling 90% Success Rate for Remplir in Real World Study
April 27, 2026
Q3 FY26 Investor Presentation
April 19, 2026
First Surgical Use of Remplir in US Department of Defense
April 16, 2026
OCC Secures Access to 221 U.S. Military Medical Centres
April 14, 2026
Remplir Used in 23 Surgeries in Ukrainian soldiers
March 17, 2026
Orthocell Appoints UK Distributor for Remplir
March 9, 2026
Appendix 4D & Half-Year Financial Report
February 23, 2026
Orthocell Receives $3.0m R&D Tax Refund
February 18, 2026
US Market and Operational Update
February 1, 2026
Quarterly Activity Report & Appendix 4C
January 18, 2026
Orthocell Posts Seventh Straight Record Revenue Quarter
January 5, 2026
Orthocell Hits US Milestone - 100 Remplir Units Sold.
December 17, 2025
Remplir Regulatory Application for US$750m EU-UK Market
December 14, 2025
First Commercial Sales of Remplir Achieved in Hong Kong
December 9, 2025
Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum with ~100 Surgeries Now Performed with Multiple Su...
November 20, 2025
Remplir gains momentum in nerve-sparing prostate surgery
November 19, 2025
2nd Distributor in Canada, Entire $75m Market Now Covered
November 4, 2025
Remplir Launches in Hong Kong with First Surgical Case
November 2, 2025
HK Distributor Signed as Remplir Expands in the Asian Market
October 28, 2025
OCC Secures Rights to High-Value Bone Regeneration Tech
October 19, 2025
$30m Placement Sees Orthocell Positioned for Rapid Growth
October 16, 2025
Trading Halt
October 14, 2025
Another Record Revenue Quarter for Orthocell
October 1, 2025
First Distributor signed for Remplir in $75m Canadian Market
September 29, 2025
Globally Significant Opportunity Emerges as Remplir™ is used in Nerve-Sparing Prostate Cancer Surgery
September 16, 2025
Remplir Use in Prostate Surgery Signals Global Opportunity
September 15, 2025
Remplir™ Study Delivers Compelling 81% Success Rate
September 8, 2025
Compelling 81% Success Rate for Remplir
September 7, 2025
Appendix 4E & Annual Report
August 29, 2025
Orthocell Announces First US Remplir Sales Revenue
July 9, 2025
Record Revenue of $2.73m in June 25 Quarter up 22.8% QoQ
June 30, 2025
First Surgical Use of Remplir in US$1.6 Billion US Market
June 26, 2025
Compelling Data Highlights Remplir Competitive Advantage
June 18, 2025
Remplir Approved to Commence Sales in the Hong Kong Market
May 11, 2025
12 Distributors Signed for Remplir Covering 21 States in US
May 8, 2025
Remplir Approved to Commence Sales in US$75m Canadian Market
April 29, 2025
Replacement Trading Halt
April 29, 2025
Pause in Trading
April 29, 2025
Remplir Approved to Commence Sales in US$84M Thai Market
April 27, 2025
First US Distributors Signed for Remplirs US$1.6B market
April 23, 2025
Regulatory Approval for Striate in US$65M Brazilian Market
April 8, 2025
Remplir Cleared to Commence Sales in US$1.6B US Market
April 3, 2025
Investor Presentation - US FDA 510(k) Clearance for Remplir
April 3, 2025
First Sales of Striate in Germany, Austria & Swiss Region
March 25, 2025
Regulatory approval to commence Striate sales in Singapore
March 17, 2025
S&P DJI Announces March 2025 Quarterly Rebalance
March 7, 2025